Policy Analysis: Life Sciences, Policy
Horizon 2020 Special Coverage
Horizon 2020 – New Commission, new Agenda
The 2015 Science|Business Horizon 2020 Conference
Brussels - 24 March 2015
The EU Energy Challenge: Can innovation fill the gap?
The EU’s transition to a sustainable energy system is a top policy challenge of the coming decade. Though much progress has been achieved, the pace of change is too slow.
Square - Brussels Meeting Centre - 13 November 2014
Helping Europe Innovate
The Annual Report 2013-2014 is a summary of the activites of the Science|Business Innovation Board over the past year. The Science|Business...
Published:
EU-US plans for joint funding of rare diseases research unveiled to industry

A new transatlantic alliance showcased its ambition to develop diagnostics for 8,000 rare diseases and double the number of registered Orphan drugs for rare conditions by 2020, at the Biotechnology Industry Organization (BIO) meeting in Washington


The European Commission's Director of Public Health Andrzej Rys said rare diseases will continue to be a priority in the next research programme, Horizon 2020 Photo: Charité, Berlin

The European Commission and the US National Institutes of Health (NIH) is putting together a jointly-funded programme of research to capitalise on advances in genomics and speed up the development of diagnostics and treatments for rare diseases.

The International Rare Disease Research Consortium (IRDiRC) set up by the Commission and the NIH to drive the plan, will hold a meeting in Montreal, Canada in October to finalise its research agenda, following two earlier meetings to set objectives...



Related subjects: Biotechnology, European Commission, European Union, USA, personalised healthcare

Advertisement